Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windlas BiotechNSE:WINDLAS -0.64%87 EV-to-EBIT is 16.72 as of Aug. 05, 2026, which is 16% above its 10-year median of 14.47. GuruFocus rates NSE:WINDLAS with a GF Score™ of 87/100 and a GF Value™ of ₹949.61 (Fairly Valued). The stock has 1 warning sign investors should review. Among 690 Drug Manufacturers companies, Windlas Biotech ranks worse than 53.19% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Windlas Biotech's Enterprise Value for the quarter that ended in Mar. 2026 was ₹13,114 Mil.
Windlas Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹918 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech EV-to-EBIT Related Terms
Windlas Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's EV-to-EBIT falls into.
Windlas Biotech's current Enterprise Value is ₹15,345 Mil.
Windlas Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹918 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a EV-to-EBIT of 16.72 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Windlas Biotech and its competitors. This is 16% above median its historical median of 14.47. Over the past decade, Windlas Biotech's EV-to-EBIT has ranged from 5.53 to 29.47. According to the industry distribution chart, Windlas Biotech ranks #367 out of 690 companies in the Drug Manufacturers industry, placing it in the top 53.2%.
Is Windlas Biotech's EV-to-EBIT too high?
Windlas Biotech's current EV-to-EBIT of 16.72 is 16% above median its 10-year median of 14.47. Over the past 10 years, this metric has ranged from a low of 5.53 to a high of 29.47. The Drug Manufacturers industry median EV-to-EBIT is 15.57. Windlas Biotech's value of 16.72 is 7.4% above this industry median. Based on the distribution chart, Windlas Biotech ranks #367 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #367 out of 690 companies for EV-to-EBIT. This places Windlas Biotech in the lower half of its industry. The industry median EV-to-EBIT is 15.57. Windlas Biotech's value of 16.72 is 7.4% above this benchmark. Historically, Windlas Biotech's own EV-to-EBIT has ranged from 5.53 to 29.47 over the past decade. While the company's 10-year median is 14.47 vs. the industry median of 15.57, Windlas Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.57, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current EV-to-EBIT of 16.72 is 7.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current EV-to-EBIT is 16.72, which is 16% above median its own 10-year median of 14.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹949.61, compared to a current price of ₹862.25 — trading 9.2% below its estimated fair value. The current EV-to-EBIT is 16.72, which is 16% above median its 10-year median of 14.47 and 7.4% above the Drug Manufacturers industry median of 15.57. Windlas Biotech's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current EV-to-EBIT is 16.72 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹862.25 is trading 9.2% below its estimated GF Value™ of ₹949.61.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
EV-to-EBIT: 16.72 (16% above median its 10-year median of 14.47)
GF Value™: ₹949.61 vs. price of ₹862.25 (9.2% below fair value)
Industry Position: 7.4% above the Drug Manufacturers median (#367 of 690)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
87GF Score
Get the complete analysis for NSE:WINDLAS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
